Short answer
Aldeyra Therapeutics, Inc. (ALDX) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$3M
- +65.2% YoY
- EPS (diluted)
- −$0.06
- +64.7% YoY
Source: XBRL data from the Aldeyra Therapeutics, Inc. (ALDX) Q1 2026 10-Q on SEC EDGAR. USD.
Aldeyra Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0; no products approved for sale and no product-candidate sales revenue
- Operating loss $3.5M vs $10.4M YoY; operating margin figures not disclosed
- R&D expense $2.4M vs $7.4M, down $5.0M; late-stage candidates 15% of R&D spending
- Cash and equivalents $65.0M at March 31, 2026; $15.0M Hercules debt repaid April 1
- AbbVie option unexercised as of May 7, 2026; operating losses expected for the foreseeable future
Risk Factors
- Newly intensified regulatory risk: FDA’s March 17, 2026 Complete Response Letter cited inconsistent study results and insufficient evidence for reproxalap efficacy
- Most material update: potential reproxalap approval now depends on addressing FDA concerns at a scheduled Type A meeting
- Compliance risk: FDA “radical transparency” policy may publicly release future Complete Response Letters, exposing clinical and regulatory information
- Near-term operational risk: FDA may require additional studies before reconsidering reproxalap, delaying approval and commercialization
- Financial risk: failure of AbbVie to exercise its option could leave Aldeyra responsible for funding further development and commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aldeyra Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.